By Jeff Overley (April 9, 2022, 5:46 p.m. EDT) – The Multidistrict Litigation Court Panel unexpectedly ruled Friday night that a huge and historic MDL for the opioid crisis lawsuits against pharmaceutical companies has achieved key goals and does not offer enough remaining benefits to justify adding future cases.
Friday’s decision observed that the collection of more than 3,000 lawsuits relating to the country’s drug abuse epidemic has – since its formation in late 2017 – put the finishing touches to joint discovery, generated far-reaching settlements and launched landmark trials to test allegations surrounding the marketing and distribution of addictive painkillers.
This is the kind of streamlining and resolution that most MDLs aim for…
Stay one step ahead
In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.
Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and more!